Emergent BioSolutions (EBS) opened 2026 with Q1 revenue of US$156.1 million and basic EPS of US$0.13, alongside trailing 12 month revenue of US$676.8 million and a TTM basic EPS loss of US$0.16. This gives investors a fresh look at how current margins compare with a still unprofitable recent track record. Over the past few quarters, the company has seen quarterly revenue move between US$140.9 million and US$231.1 million, with basic EPS swinging from a loss of US$1.04 in Q4 2025 to a profit of US$1.25 in Q1 2025 and then back to smaller profits and losses. This latest print lands in the middle of that volatility as the market weighs whether revenue strength is starting to support more stable profitability.

See our full analysis for Emergent BioSolutions.

With the headline numbers on the table, the next step is to set these results against the prevailing stories about Emergent BioSolutions to see which narratives around growth and margins line up with the data and which ones are challenged by it.

TTM earnings still show US$8.6 million loss

• On a trailing 12 month basis to Q1 2026, Emergent BioSolutions reported total revenue of US$676.8 million with a net loss of US$8.6 million and basic EPS of US$0.16 loss, so the company remains unprofitable even though Q1 itself showed a US$6.8 million profit.
• Analysts' consensus view talks about improved operating efficiency and a stronger balance sheet supporting better earnings potential, yet the trailing data still show losses of US$8.6 million and TTM EPS in loss territory, which means:
  • Claims about improved earnings potential are not yet mirrored in the aggregate numbers, as TTM net income is still negative despite profitable quarters like Q1 2026 and Q3 2025.
  • The consensus emphasis on greater earnings stability sits against EPS that has swung between a US$1.04 loss and a US$1.25 profit quarter to quarter, so stability is not yet visible in the recent history.

Revenue growing faster than forecast earnings

• Trailing 12 month revenue growth is cited at about 15.6% per year and analysts expect revenue to reach US$962.9 million by 2029, while the same set of forecasts points to earnings of only US$301,600 and EPS of US$0.01 by that time.
• Bulls highlight growing government demand and international expansion as drivers of more predictable revenue and higher earnings potential, but the figures in the forecast create tension with that view, because:
  • Analysts assume profit margins will move from 7.1% to 0.0% over the next three years, which sits awkwardly with a bullish case built on improved operating leverage and higher margins.
  • The projection that earnings fall from US$52.6 million on a trailing basis to US$301,600 in 2029 suggests that, while revenue growth is expected, analysts are not currently baking in stronger profitability to match it.

Bulls point to contract wins and global health spending as reasons to stay optimistic even with modest profit forecasts, so if that angle interests you, check out the full bullish thesis here 🐂 Emergent BioSolutions Bull Case.

Low P/S and large DCF gap vs US$8.47 share price

• Recent valuation work in the dataset shows Emergent BioSolutions trading on a P/S of about 0.6x compared with around 11x for the wider US biotech industry and 17.2x for peers, while the current share price of US$8.47 is well below a stated DCF fair value of about US$74.84.
• Bears focus on the risk that the company remains unprofitable, with losses having grown at about 24.4% per year over the past five years and forecasts not showing a return to profitability within three years, which matters even with low multiples because:
  • TTM net income of US$8.6 million loss and EPS of US$0.16 loss mean that any comparison between the US$8.47 share price and US$74.84 DCF fair value still relies on the assumption that future cash flows improve from today’s loss making base.
  • The need for a P/E of 2,351.6x on the 2029 earnings estimate of US$301,600 to justify a US$12.00 price target shows how much of the bearish concern is about earnings staying thin even if revenue grows.

Skeptics argue that very low P/S and a large gap to DCF fair value only matter if profits eventually follow, so if you want to see how that cautious view is built from the numbers, it is worth reading the full bear case 🐻 Emergent BioSolutions Bear Case.

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Emergent BioSolutions on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Mixed messages in the data can be useful, so use that tension to push you to look closer, move quickly and shape your own view by checking the 3 key rewards and 1 important warning sign.

See What Else Is Out There

Emergent BioSolutions combines revenue growth with an unprofitable TTM record, thin forecast earnings and wide EPS swings, which leaves profitability and stability questions unresolved.

If you want to balance that uncertainty with companies that screen for strength, check out the 67 resilient stocks with low risk scores to compare options that may better match your comfort level.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.